CD276 and glioblastoma: Qi and colleagues demonstrated that an eight-gene risk signature based on fatty acid catabolic metabolism in glioblastoma had high prognostic value and that this signature significantly correlated with gene expression of the immune checkpoint markers B7-H3 (CD276) and HAVCR2 (TIM-3) [96].